Can I Take Glycine with Trazodone?

What Is Trazodone and Why Do People Take It at Bedtime?

Trazodone is an FDA-approved antidepressant that works as a serotonin antagonist and reuptake inhibitor. At antidepressant doses (150 to 400 mg/day), it blocks serotonin transporters. At the lower doses used off-label for insomnia (25 to 150 mg), the dominant clinical effect comes from antagonism of histamine H1 and serotonin 5-HT2A receptors, both of which are strongly sedating when blocked.

The drug has a half-life of roughly 5 to 9 hours for the parent compound (trazodone) and 5 to 9 hours for its active metabolite m-chlorophenylpiperazine (mCPP). CYP3A4 is the primary metabolic enzyme. [1]

Why Prescribers Choose Trazodone for Sleep

Because trazodone lacks the dependence liability of benzodiazepines and Z-drugs, many clinicians prefer it for chronic insomnia, particularly in patients with co-occurring depression or anxiety. The 2017 American Academy of Sleep Medicine (AASM) Clinical Practice Guideline states that evidence for trazodone in chronic insomnia disorder "is insufficient to recommend for or against use," yet real-world prescribing remains high given its tolerability profile. [2]

Trazodone's CNS Depression Profile

At bedtime doses, trazodone measurably suppresses sleep-onset latency and increases slow-wave sleep in polysomnographic studies. A 2020 crossover study (N=24) found 100 mg trazodone reduced sleep-onset latency by 9.0 minutes versus placebo (P<0.01). [3] That CNS-depressant fingerprint is directly relevant when layering any other sedation-promoting supplement on top.

What Is Glycine and How Does It Affect Sleep?

Glycine is the simplest amino acid, found in collagen-rich foods like bone broth and gelatin. It is not an essential amino acid because the liver synthesizes roughly 3 g/day endogenously, though dietary and supplemental intake can substantially raise plasma and cerebrospinal fluid levels.

In the CNS, glycine acts at two distinct sites: as the obligate co-agonist at NMDA receptors (binding the GluN1 subunit glycine site), and as an inhibitory neurotransmitter at strychnine-sensitive glycine receptors (GlyRs) in the spinal cord and brainstem. [4]

Glycine's Sleep-Specific Mechanism

The sleep-promoting effect of glycine is thought to operate through two pathways. Peripherally, glycine lowers core body temperature by dilating cutaneous blood vessels, and the drop in core temperature is a well-established trigger for sleep onset. Centrally, it modulates NMDA receptor activity in the suprachiasmatic nucleus, the brain's circadian pacemaker.

A randomized, placebo-controlled crossover trial by Bannai et al. (N=11) published in Sleep and Biological Rhythms found that 3 g glycine taken before bedtime significantly improved subjective sleep quality scores (Fatigue Severity Scale, Mini-Mental State Examination performance the next morning) versus placebo. [5] A follow-up polysomnographic study by the same group (N=11) confirmed shorter sleep-latency and preserved slow-wave sleep architecture after glycine 3 g at bedtime. [6]

Glycine and Blood Glucose

Glycine also has a modest incretin-like effect. A 2018 meta-analysis (7 trials, N=350) found glycine supplementation reduced fasting blood glucose by a mean of 2.7 mg/dL and HbA1c by 0.12% in people with metabolic syndrome. [7] This is directly relevant when combined with trazodone, which itself has been associated with modest fasting glucose reductions in some observational data.

The Trazodone-Glycine Interaction: Pharmacokinetic vs. Pharmacodynamic

This is the central clinical question. The interaction between glycine and trazodone is almost entirely pharmacodynamic, meaning both substances act through different molecular mechanisms that converge on the same clinical outcome (sedation) rather than one substance altering the blood levels of the other.

Pharmacokinetic Assessment: Low Concern

Trazodone is metabolized primarily by CYP3A4 and secondarily by CYP2D6. Glycine is not a known inhibitor or inducer of either enzyme based on current in vitro data. No published pharmacokinetic interaction study has identified glycine as altering trazodone plasma concentrations. [8]

Glycine's oral bioavailability is high, and it is excreted as CO2 and water after transamination. Its renal clearance pathway does not share transporters with trazodone's renal elimination. The theoretical pharmacokinetic risk is low.

Pharmacodynamic Assessment: Moderate Concern at Higher Doses

Both agents depress CNS arousal through distinct but convergent pathways. The table below maps their mechanisms side by side.

| Mechanism | Trazodone | Glycine | |---|---|---| | Histamine H1 antagonism | Yes (sedating) | No | | 5-HT2A antagonism | Yes (sedating) | No | | GlyR agonism (inhibitory) | No | Yes | | NMDA co-agonism | No | Yes (via GluN1 site) | | Core body temperature reduction | Indirect | Direct (vasodilation) | | Alpha-1 adrenergic antagonism | Yes (orthostatic hypotension risk) | No |

Because the mechanisms do not fully overlap, the interaction is additive rather than synergistic. Additive sedation at typical doses (trazodone 50 to 100 mg + glycine 3 g) is clinically manageable for most adults. The risk becomes meaningful at trazodone doses of 150 mg or more, particularly in older adults whose drug clearance is already reduced.

HRX Stacking Decision Framework: Glycine + Trazodone

Use this 4-question screen before adding glycine to a trazodone regimen:

1. Is the trazodone dose 150 mg or higher? If yes, discuss with prescriber before adding glycine.
2. Are you also taking a benzodiazepine, Z-drug, opioid, or gabapentinoid? If yes, do not add glycine without explicit prescriber sign-off.
3. Do you have type 2 diabetes or impaired fasting glucose? If yes, monitor fasting glucose weekly for the first 4 weeks after adding glycine.
4. Are you 65 years or older? If yes, start glycine at 1.5 g (half the standard dose) and reassess after 2 weeks.

CNS Sedation: Additive Effect in Practice

The clinical concern most patients and clinicians need to weigh is next-morning sedation and psychomotor impairment. Trazodone alone at 100 mg has been shown to impair simulated driving performance for up to 6 hours post-dose in healthy volunteers. [9] Adding glycine 3 g has a modest additional sedating effect that may extend residual drowsiness.

Who Faces the Highest Sedation Risk?

The risk profile is not uniform. Adults over 65, people with hepatic impairment (CYP3A4 activity reduced 30 to 50% in mild cirrhosis), and patients already taking other CNS depressants face proportionally higher additive sedation. For these groups, the FDA's 2019 guidance on CNS-depressant drug combinations recommends explicit informed consent and close follow-up. [10]

Patients with obstructive sleep apnea (OSA) deserve special mention. Trazodone has a complex relationship with OSA: some small trials suggest mild improvement in apnea-hypopnea index, while others show no change. Glycine's vasodilatory and muscle-relaxing properties have not been studied in OSA patients. Until dedicated data exist, patients with untreated or poorly controlled OSA should discuss this combination with their sleep specialist.

Practical Mitigation Strategies

If a patient decides to proceed with the combination after discussing it with their prescriber, three steps reduce risk.

Start glycine at 1.5 g rather than 3 g for the first two weeks, then titrate up if morning functioning is unaffected. Take both agents at the same time (30 minutes before bed) so sedation peaks during the first half of the sleep cycle rather than spilling into morning hours. Avoid alcohol entirely on nights when both supplements are used; alcohol adds a third layer of CNS depression through GABA-A potentiation.

Glycine's Glycemic Effect and Trazodone's Metabolic Profile

Both glycine and trazodone have modest but measurable effects on glucose metabolism, and the combination warrants attention in patients with diabetes or prediabetes.

Trazodone and Glucose Regulation

Trazodone is among the antidepressants considered metabolically neutral, unlike second-generation antipsychotics and some tricyclics. A retrospective cohort study (N=12,144) published in Diabetes Care found that trazodone use was not associated with new-onset type 2 diabetes, compared to a statistically significant risk increase with mirtazapine (odds ratio 1.36, 95% CI 1.19 to 1.55, P<0.001). [11] Some researchers hypothesize that trazodone's H1 antagonism, the same mechanism that underlies its sedation, may contribute to mild weight gain and subtle insulin resistance at high chronic doses, though evidence in humans is limited.

Glycine as a Glucose-Lowering Agent

As noted above, glycine supplementation at 3 to 15 g/day has shown consistent, modest reductions in fasting glucose in metabolic syndrome populations. [7] The mechanism appears to involve improved glucagon-like peptide-1 (GLP-1) secretion, reduced glucotoxicity in pancreatic beta cells, and direct enhancement of insulin sensitivity in skeletal muscle.

For most patients, this glycemic effect is beneficial. For patients on insulin or sulfonylureas, an unexpected additive glucose-lowering effect could increase hypoglycemia risk. Patients in these categories should check fasting glucose twice weekly for the first 30 days after starting glycine alongside trazodone and report readings below 70 mg/dL to their prescriber.

Collagen Synthesis: A Separate Reason Some People Take Glycine

Many patients who ask about this combination are taking glycine not for sleep but for its role in collagen synthesis. Glycine constitutes roughly 33% of the amino acid residues in collagen, and supplemental glycine has been studied in the context of skin elasticity, joint health, and post-exercise recovery.

This use-case does not create additional interaction risk with trazodone, because the doses typically used for connective tissue support (5 to 10 g/day, often split across multiple meals) are taken throughout the day rather than concentrated at bedtime. The pharmacodynamic overlap with trazodone's sedating effect is minimal when glycine doses are spread across waking hours.

A 2018 randomized controlled trial (N=106) found that 10 g/day hydrolyzed collagen (which delivers approximately 3 g glycine) for 24 weeks improved skin elasticity scores compared to placebo (P<0.05). [12] No drug interactions with common medications were reported in that trial's adverse event analysis.

Serotonin Syndrome Risk: Does Glycine Play a Role?

Serotonin syndrome is the most serious acute risk associated with trazodone. Combining trazodone with other serotonergic agents (MAOIs, linezolid, high-dose SSRIs, tramadol) can produce life-threatening hyperthermia, rigidity, and autonomic instability.

Glycine is not a serotonergic compound. It does not inhibit serotonin reuptake, stimulate 5-HT receptors, or increase serotonin synthesis. The Hunter Serotonin Toxicity Criteria, the most validated diagnostic tool for serotonin syndrome, identifies no glycine-mediated serotonergic mechanism. [13]

Patients already on trazodone should be careful about any new supplement marketed as a "mood booster" or "serotonin support," as some contain 5-HTP or L-tryptophan that could raise serotonin levels. Plain glycine powder or capsules without these additions carry no meaningful serotonin syndrome risk when combined with trazodone.

Alpha-1 Antagonism and Orthostatic Hypotension

Trazodone blocks alpha-1 adrenergic receptors. This is why orthostatic hypotension (a drop in blood pressure upon standing) is a recognized adverse effect, particularly at doses above 150 mg and in elderly patients. Trazodone-induced orthostatic hypotension contributed to a black-box-era warning and remains in the drug's prescribing information. [1]

Glycine, through its vasodilatory effect on peripheral blood vessels (the same mechanism that lowers core body temperature), could theoretically add to blood pressure reduction in predisposed individuals. No clinical trial has quantified this additive effect. Patients who already experience lightheadedness on trazodone should use extra caution when rising from bed after taking both agents together, particularly in the first two to four hours after the bedtime dose.

What the Evidence Is Missing

Two gaps in the literature are worth naming explicitly. No published randomized trial has examined glycine and trazodone co-administration in human subjects. All risk estimates above are extrapolated from single-agent pharmacology. Second, the Natural Medicines Comprehensive Database (NMCD), the most widely used clinical reference for drug-supplement interactions, currently classifies the glycine-trazodone combination as "insufficient evidence to rate," meaning it is neither flagged as a major interaction nor cleared as safe by formal evidence review.

This evidence gap means the combination sits in a gray zone. Gray zone does not mean dangerous by default, but it does mean patients should loop in their prescriber rather than making the decision unilaterally.

Monitoring Protocol If You Are Already Taking Both

If a patient is already combining glycine and trazodone, a short monitoring checklist is practical and low-burden.

First two weeks: rate morning alertness daily on a 1 to 10 scale. A score of 5 or below two days in a row warrants a call to the prescriber. Check standing blood pressure the morning after the first combined dose and again at 7 days. For patients with diabetes: fasting glucose twice weekly as described above.

At 30 days: review the morning alertness ratings with the prescriber. If subjective next-morning cognition is unimpaired and no cardiovascular symptoms have emerged, continuation is generally reasonable at the doses being used.

Discontinuation: if glycine is stopped after prolonged use, trazodone's effect does not change materially because no pharmacokinetic dependence was established. No taper is needed for glycine itself, as it is not physiologically habit-forming.

Practical Dosing Guidance

At the doses most commonly studied and sold (glycine 3 g, trazodone 50 to 100 mg), the combination is manageable for healthy adults without compounding CNS depressants. Several practical points follow from the pharmacology reviewed above.

Take both at the same time 30 minutes before sleep. Do not take glycine in the morning or afternoon if the sole goal is sleep augmentation; daytime glycine doses do not produce meaningful sedation but also do not amplify trazodone's next-morning residual effects. For patients taking trazodone doses of 150 mg or higher, glycine should not be added without prescriber review. For patients over 65, the starting dose of glycine should be 1.5 g, not 3 g.

The FDA has not approved glycine as a drug for any indication. Its use as a dietary supplement is governed by DSHEA (1994), which means manufacturers do not need to demonstrate safety or efficacy before sale. Third-party-tested products (NSF Certified for Sport, USP Verified, or Informed Sport) reduce the risk of label inaccuracies and undisclosed contaminants.